There came out the final ruling that it is reasonable to refuse the registration of a patent of Telmisartan for the purpose of diabetes treatment

There came out the final ruling that it is reasonable to refuse the registration of a patent of Telmisartan for the purpose of diabetes treatment.

Behringer applied for a patent in January 2006, but the Korean Intellectual Property Tribunal refused it and it was not registered. Behringer refused to the decision of Tribunal and appealed to the court above, Patent Court in last 2011. However, th...